What is #MissionCancer?
Partly inspired by the Apollo 11 mission to put a man on the moon, the European research and innovation missions have been conceived to come up with solutions to some of the greatest challenges facing our world. Cancer has been identified as one of the 5 mission areas.

Essential IMI-cancer figures

- IMI has launched 11 cancer projects since 2010
- €130 million research funding dedicated
- Research taking place in 19 different countries
- Over 200 partners involved

Future funding

3 research topics on cancer were included in IMI’s most recent funding calls:

- Why do some cancer cells become resistant to a drug after initially responding well?
- Is proton therapy better than radiotherapy for treating certain cancers?
- What new tools, models and standards will help make engineered T-cell therapies safer and more effective?

Sample projects

- Developing preclinical models of paediatric tumours to help develop cancer drugs for children
  ITCCP4
- Developing less invasive ways of capturing tumour samples (liquid biopsy)
  CANCER-ID
- Using big data to deliver information that will help to improve the care of patients with blood cancers
  HARMONY
- Using big data to improve the screening, diagnosis and treatment of prostate cancer patients
  PIONEER

What is IMI?

IMI is a public-private partnership that was set up to make progress in the development of medicines to treat some of Europe’s most burdensome diseases. The best researchers from industry, academia and SMEs work together to break through the research roadblocks that are stalling the development, testing and licensing of new drugs and treatments. For every euro the Commission contributes, the private sector matches it in in-kind contributions. Ebola, Alzheimer’s and cardiovascular disease are among the disease areas in the IMI project portfolio.